Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Exclusion Criteria

• •Participants with known EGFR and ALK AGAs; documented negative results for EGFR and ALK AGAs are required for participants with non-squamous histology.
• •Participants with CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
• •Participants with clinically significant risk of hemorrhage or fistula are excluded.
• •Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
• •Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1.
• •Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody.
• •History of allogeneic organ / hematopoietic stem cell transplantation.
• •Participants with any of the following respiratory conditions:
• •* Evidence of noninfectious or drug-induced interstitial lung disease (ILD) or pneumonitis
• •* Grade ≥3 pulmonary disease unrelated to underlying malignancy
• •History of uncontrolled comorbidities within 6 months prior to the first dose including uncontrolled cardiac and cerebrovascular conditions, hypertension, diabetes, significant vascular disease or arterial/severe venous thromboembolic events.
• •Major surgery \< 4 weeks or minor surgery \< 3 days prior to first dose of study intervention.
• •History of severe bleeding tendency or coagulation dysfunction
• •History of esophageal varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose.
• •Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV).
• •Participants with history of immunodeficiency
• •Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior (in the past 5 years) or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.
• •Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.